A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Hormone Receptor-positive Breast Cancer|Hormone Therapy
Interventions: DRUG: Palbociclib|DRUG: Ribociclib|DRUG: Abemaciclib|DRUG: Letrozole
Sponsor: National Taiwan University Hospital